Systemic lupus erythematosus is associated with an increased risk for pulmonary manifestations, including ILD and pulmonary hypertension.

To assess how a patient with pulmonary arterial hypertension (PAH) is faring on therapy, look at the right heart, said Anjali ...

In pulmonary hypertension, a combination of metabolic and mechanical dysfunction leads to irreversible vascular damage.

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

A complete appraisal, in physiologic terms, of the mechanism of pulmonary hypertension in heart disease must take into account these three factors, which may operate independently or ...

Exclusive e-cigarette use is significantly associated with new cases of chronic obstructive pulmonary disease.

A new study published in The New England Journal of Medicine showed that for high-risk patients with pulmonary arterial ...

E-cigarette use is linked to increased risk of COPD and possibly hypertension, though less harmful than traditional smoking, ...

As cardiovascular disease remains a leading cause of ... changing treatments for patients with complex conditions like pulmonary hypertension. More information: Mohamed Riad Abouzid et al ...

Pulmonary arterial hypertension (PAH ... "Sotatercept gives us the opportunity to control the disease in a completely new way—even in patients who were previously considered untreatable despite ...

Commercial stage pharmaceutical firm Shield Therapeutics, which has a base in Gateshead, has entered into an exclusive licence agreement to commercialise its oral iron therapy drug in Japan.

and a high 1-year risk of death (Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management Lite 2 risk score, ≥9) who were receiving the maximum tolerated dose ...